Analysis
Simile raised a $200 million Series B led by Greenoaks at a $2 billion valuation, just five months after closing a $100 million Series A -- a step-up that reflects how quickly investor conviction has built around the company's approach to simulating human behavior with AI. Index Ventures returned as a backer, alongside Bain Capital Ventures, A*, Factory and new investor CVS Health Ventures.
The company's platform is built to model how real populations of people will respond to a product change, a marketing message, or a policy decision before it ever reaches actual customers, using a foundation model trained specifically on human behavioral data rather than general-purpose text and code. Enterprises use it to run large numbers of simulations against synthetic populations, catching problems or validating strategies at a fraction of the cost and time of traditional market research or live A/B testing.
“The company plans to use the new capital to build out its foundation model for human behavior further and expand its enterprise sales motion.”
CVS Health's direct investment is a notable signal: the healthcare giant is both a customer and now a financial backer, having already used Simile's simulated populations to study drivers of patient satisfaction and test strategies around medication adherence -- practical, revenue-relevant use cases rather than experimental pilots.
Simile says total revenue has grown fivefold since its public launch, and the company has now run tens of millions of simulations for Fortune 100 clients, giving the round real usage data to back up its valuation rather than relying purely on model capability or hype. The company plans to use the new capital to build out its foundation model for human behavior further and expand its enterprise sales motion.
For AI investors, Simile represents a narrower and arguably more defensible category than general-purpose foundation models: proprietary behavioral data as the moat, rather than raw model scale. What to watch: whether Simile's simulation accuracy holds up under scrutiny as more enterprises deploy it for higher-stakes decisions, and whether competitors with access to similarly large behavioral datasets -- social platforms and retailers among them -- move into the category.
